1.Effects of 5-Aza-2'-deoxycytidine on proliferation of human gastric cancer BCG-823 cells and the expression of HOXA5 gene
Zhixue FANG ; Zhongcheng HUANG
Journal of Chinese Physician 2016;18(12):1825-1828
Objective To explore the effects of 5-Aza-2'-deoxycytidine (5-Aza-CdR) on the proliferation of BCG-823 human gastric cancer cells and the expression of HOXA5.Methods The methylation status of the promoter of HOXA5 was measured by methylmion specific PCR (MSP).The BCG-823 cells were treated with different concentrations of 5-Aza-CdR,and then the changes of expression and methylation status of HOXA5 gene were detected by quantitative real-time polymerase chain reaction (QRT-PCR),Western-blot,and MSP.Cells proliferation was assessed by methyl thiazolyl tetrazolium (MTT) assay.Results (1) Different methylation status of HOXA5 gene promoter was detected in BCG-823 cells.The mathylation rate of HOXA5 gene promoter were reduced after treatment with 5-Aza-CdR,and also were negatively related to the concentration of 5-Aza-CdR (F =438.307,P < 0.01).(2) Compared to the control groups,the expressions of HOXA5 mRNA and protein were increased after treatment with 5-Aza-CdR,with statistical significance (P < 0.05).(3) The proliferation rate of BCG-823 cells was significantly inhibited (P <0.05).Conclusions The methylation status of HOXA5 promoter was detected in BCG-823 cells.5-AzaCdR is able to inhibit BCG-823 cells growth in vitro,which might be related to the expression of HOXA5.It may be a new way to treat gastric cancer.
2.The safety and efficacy of mouse nerve growth factor for peripheral neuropathy associated With n-hexnae intoxication
Zhixue ZHAN ; Liying LIN ; Weiwei LIU ; Yunxiang FANG
Chinese Journal of Primary Medicine and Pharmacy 2009;16(9):1580-1582
Objective To evaluate the efficacy and safety of mNGF to peripheral neuropathy induced by n-bexane. Methods 54 cases were treated with mNGF (18 μg i. m qd.) and the period of treatment is 56 days. 15 severe cases treated with two periods of treatment. Subjects received symptoms and signs of nerve system and activi-ties of daily living (ADL) scale were examined before and every 14 days after treated, The efficacy of mNGF was as-sessed by score increase of each index before and after treatment himself. To evaluate the safety, subjects received Is-boratory examinations before and every 28 days after treated, recorded adverse events everyday. Results During the trial, The indexes had improved remarkably in two weeks after the treatment , There were highly significant differ-ences in score increase after 4 ~ 8 weeks of treatment(P < 0. 01). It indicated that treatmented with mNGF was effec-tive. There were no severe adverse events (SAE) found among 54 trial subjects. There were no evident abnormalities in laboratory examinations before and after treatment. Pains of the injected sites are the main ADR, the incidence was 68.5% (37/54). Conclusion The results of the research indicated that mNGF clinical application could be consid-ered as safe and effective.
3.Multidisciplinary-team approach in diagnosis and treatment of patients with chronic constipation.
Zhixue FANG ; Zhongcheng HUANG
Chinese Journal of Gastrointestinal Surgery 2017;20(12):1342-1344
Chronic constipation is one of the common diseases in clinic. For the complicated causes and pathophysiology, the overall efficacy is not satisfactory in the traditional medical model. Multidisciplinary-team (MDT) approach is a new team medical model, which is also an important systematic and modular medical approach. Treating patients with chronic constipation by multidisciplinary-team approach is an effective way to improve the overall efficacy. In diagnosis, MDT approach can get more accurate and explicit diagnosis and type of the constipation by gathering patients' detailed medical history, complete physical examination, laboratory and image test, patients' mental and nutritional condition. In treatment, MDT members can cooperate in various fields, such as basic research, medicine, physics, psychology, surgery and conversion therapy, and that may provides more thoughts and methods for the treatment of chronic constipation.
4.Application effect of intermittent fasting combined with diversified management mode in weight loss of overweight and obese people
Fang CHEN ; Zhixue GUO ; Shaoting WANG ; Zhong PAN ; Hongmei DONG ; Xin FENG ; Xizhuo WANG ; Meixia LIU ; Xiaoyong MA
Journal of Clinical Medicine in Practice 2024;28(7):72-74,84
Objective To explore the effect of intermittent fasting combined with diversified man-agement mode on weight loss of overweight and obese people.Methods A total of 120 overweight and obese patients were selected as research objects,and randomly divided into control group(n=60)and experimental group(n=60).The control group was given intermittent fasting,and the experimental group was given diversified management mode on the basis of the control group.Waist circumference,body mass,body mass index(BMI),waist-to-hip ratio and blood lipid level were compared between the two groups;the scores of hunger,satiety,satisfaction and the incidence of adverse reactions were compared between the two groups.Results After intervention,waist circumference,body mass,BMI,waist-to-hip ratio,total cholesterol(TC),triglyceride(TG)and low-density lipoprotein choles-terol(LDL-C)in the experimental group were significantly lower,and high-density lipoprotein choles-terol(HDL-C)was significantly higher than that in the control group(P<0.05).After intervention,the hunger score of the experimental group was significantly lower,and the satiety score and satisfac-tion score were significantly higher than those of the control group(P<0.05).The total incidence of adverse reactions in the experimental group was 6.67%,which was significantly lower than 20.00%in the control group(P<0.05).Conclusion The application of intermittent fasting combined with diversified management mode in overweight and obese people is better,which can improve the relevant clinical indicators and blood lipid levels,and has high safety.
5.Application effect of intermittent fasting combined with diversified management mode in weight loss of overweight and obese people
Fang CHEN ; Zhixue GUO ; Shaoting WANG ; Zhong PAN ; Hongmei DONG ; Xin FENG ; Xizhuo WANG ; Meixia LIU ; Xiaoyong MA
Journal of Clinical Medicine in Practice 2024;28(7):72-74,84
Objective To explore the effect of intermittent fasting combined with diversified man-agement mode on weight loss of overweight and obese people.Methods A total of 120 overweight and obese patients were selected as research objects,and randomly divided into control group(n=60)and experimental group(n=60).The control group was given intermittent fasting,and the experimental group was given diversified management mode on the basis of the control group.Waist circumference,body mass,body mass index(BMI),waist-to-hip ratio and blood lipid level were compared between the two groups;the scores of hunger,satiety,satisfaction and the incidence of adverse reactions were compared between the two groups.Results After intervention,waist circumference,body mass,BMI,waist-to-hip ratio,total cholesterol(TC),triglyceride(TG)and low-density lipoprotein choles-terol(LDL-C)in the experimental group were significantly lower,and high-density lipoprotein choles-terol(HDL-C)was significantly higher than that in the control group(P<0.05).After intervention,the hunger score of the experimental group was significantly lower,and the satiety score and satisfac-tion score were significantly higher than those of the control group(P<0.05).The total incidence of adverse reactions in the experimental group was 6.67%,which was significantly lower than 20.00%in the control group(P<0.05).Conclusion The application of intermittent fasting combined with diversified management mode in overweight and obese people is better,which can improve the relevant clinical indicators and blood lipid levels,and has high safety.
6.Clinical efficacy of patient-specific instrumentation assisted unicompartmental knee arthroplasty
Xiangyu MENG ; Zhixue WANG ; Peng WU ; Huanming FANG ; Peng ZHAO ; Xu WANG ; Yong DING
Chinese Journal of Orthopaedics 2024;44(22):1441-1449
Objective:To investigate the postoperative prosthesis position and early clinical efficacy of 3D printing patient-specific instrumentation (PSI)-assisted unicompartmental knee arthroplasty (UKA).Methods:The clinical data of 15 patients (17 knees, PSI group) with medial compartment knee osteoarthritis who underwent PSI-assisted UKA in the Second Affiliated Hospital, the Air Force Medical University from May to August 2023 were retrospectively analyzed, matched with fifteen patients (17 knees, non-PSI group) with medial compartment knee osteoarthritis undergoing conventional UKA. The differences in the prosthesis placement positions in the postoperative X-ray films between the two groups were compared, including the coronal varus-valgus angles of the tibial and femoral prostheses, the sagittal posterior inclination angle of the tibial prosthesis, the flexion-extension angle of the femoral prosthesis, and the height of the reconstructed joint line. The indicators related to the lower limb alignment (including the femoral valgus angle, the lateral femoral angle, the hip-knee-ankle angle, and the femur-tibia angle) and the range of motion of the knee joint before and after the operation were compared. The Oxford knee score (OKS), American Knee Society (AKS) knee score and function score, and the visual analogue scale (VAS) were used to evaluate the clinical effects of the two groups.Results:In the PSI group, the coronal varus-valgus angle of the tibial prosthesis was 1.6°±0.3° after the operation, and the sagittal posterior inclination angle was 5.7°±0.8°. The coronal varus-valgus angle of the femoral prosthesis was -0.5°±1.5°, and the sagittal flexion-extension angle was 4.0°±1.9°. In the non-PSI group, the corresponding angles were 2.3°±0.6°, 4.5°±1.0°, 1.4°±1.5°, and 7.3°±2.2° respectively with significant differences between the two groups ( P<0.05). The OKS of the PSI group before and after the operation were 26.5±1.8 and 38.6±4.1 points respectively. The AKS knee score were 56.9±8.6 and 89.2±7.2 points. The AKS function score were 70.1±4.2 and 77.5±9.4 points. The VAS were 4.5±3.7 and 2.3±0.3 points, and the range of motion of the knee joint were 115.2°±4.8° and 125.9°±4.6° with significant differences ( P<0.05). The OKS of the non-PSI group before and after the operation were 25.3±6.2 and 38.2±3.5 points respectively. The AKS knee score were 50.6±9.3 and 84.5±6.6 points. The AKS function score were 73.4±3.9 and 77.2±4.8 points. The VAS were 5.8±2.4 and 2.5±1.6 points, and the range of motion of the knee joint were 113.6°±6.7° and 122.3°±5.0° with significant differences ( P<0.05). There were inter-group differences in the AKS knee score and the range of motion of the knee joint after the operation between the two groups with significant differences ( P<0.05). Conclusion:PSI guides-assisted UKA can effectively correct the lower limb alignment of patients and improve knee joint function with good short-term efficacy. Compared with conventional UKA, PSI guides-assisted UKA is less time-consuming with higher precision in prosthesis installation position and fewer post-operative complications.
7.Clinical significance of telomerase reverse transcriptase promoter mutation in radioactive iodine refractory papillary thyroid cancer
Tingting WANG ; Gangming CAI ; Yi PAN ; Heming GUO ; Sicheng LI ; Qi MA ; Zhixue YANG ; Longjiang XU ; Ji HU ; Chen FANG
Chinese Journal of Nuclear Medicine and Molecular Imaging 2022;42(2):90-95
Objective:To evaluate the influence of telomerase reverse transcriptase (TERT) promoter mutation on radioiodine uptake status of radioactive iodine refractory papillary thyroid cancer (RAIR-PTC) and radioiodine therapy response by analyzing the mutation frequency of TERT promoter in RAIR-PTC.Methods:A total of 37 patients with RAIR-PTC (15 males, 22 females, age (49.8±16.1) years) and 40 PTC patients with effective radioiodine therapy (13 males, 27 females, age (39.8±10.9) years) between January 2005 and June 2020 in JiangYuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine were retrospectively analyzed. TERT promoter mutation and B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E mutation of patients were observed. The differences across genotype patterns on radioiodine uptake status and therapy response were compared. The Fisher′s exact test and independent-sample t test were used for data analysis. Results:The incidence rate of TERT promoter mutation in the RAIR-PTC group was 40.54% (15/37, all C228T), which was significantly higher than that in the effective radioiodine therapy group (0, 0/40; P<0.001). No statistically significant difference was found for the mutation rate of BRAF V600E between the RAIR group (64.86%, 24/37) and the effective radioiodine therapy group (72.50%, 29/40; P=0.858). Patients with TERT promoter mutation were older ( t=3.76, P=0.001) and the non-intake rate of radioiodine in distant metastases of those patients was higher ( P=0.037). Furthermore, 2/3 of patients who received targeted therapies and 3/4 deaths had TERT promoter mutation. Among 35 patients with negative thyroglobulin antibody (TgAb), 11/14 of patients with TERT mutation had a rising stimulated thyroglobulin (sTg), while the percentage of the non-TERT mutation group was 57.1% (12/21; P=0.357). Conclusion:The TERT promoter mutation rate is significantly increased in RAIR-PTC patients and can serve as a prognostic predictor in RAIR.